The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.
The survey, conducted by SeraCare Life Sciences and GenomeWeb, asked more than 150 individuals working on clinical NGS about their quality control practices.
The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
Individuals with higher-than-usual mutant allele frequencies after stem cell transplantation were prone to disease progression and reduced progression-free survival.
An Oregon Health Authority committee issued a draft guidance to not cover NGS testing for solid tumors, which advocacy groups say will limit access to Medicaid beneficiaries.